Sagimet Biosciences Inc. (SGMT) Financial Analysis & Valuation | Quarter Chart
Sagimet Biosciences Inc. (SGMT)
SGMTPrice: $5.21
Fair Value: 🔒
🔒score
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment ... more
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called f... more
Description
Shares
| Market Cap | $161.52M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | David A. Happel |
| IPO Date | 2023-07-17 | CAGR | — |
| Employees | 14 | Website | sagimet.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SGMT chart loading...
Fundamentals
Technicals
| Enterprise Value | $115.62M | P/E Ratio | -2.93 |
| Forward P/E | -3.39 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 0.01 |
| P/CF Ratio | -0.01 | P/FCF Ratio | -0.01 |
| EPS | $-1.78 | EPS Growth 1Y | 28.99% |
| EPS Growth 3Y | 36.92% | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.42% | ROA | -0.45% |
| ROCE | -0.54% | Current Ratio | 13.06 |
| Quick Ratio | 13.06 | Cash Ratio | 3.55 |
| Debt/Equity | 0 | Interest Coverage | — |
| Altman Z Score | 6.63 | Piotroski Score | 1 |